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Abstract
Introduction: Inadequate glycemic control contributes to the development and progression of complications, which are associated with
a significant economic burden on healthcare systems. However, optimal glycemic control is difficult to sustain with oral antidiabetic
agents and adherence to intensive insulin regimens is compromised by patient compliance to multiple daily injections. Therefore,
alternative delivery systems are required to improve the acceptability of insulin therapy.
Aims: This review assesses the evidence for the therapeutic value of inhaled insulin (Exubera®) in the management of type 1 and type
2 diabetes.
Evidence review: Evidence indicates that glycemic control, as measured by plasma HbA1c levels, with Exubera is as effective as
subcutaneous insulin in patients with type 1 or type 2 diabetes. There is also good evidence that Exubera provides improved patient
satisfaction and ease of use compared with subcutaneous insulin. However, the cost effectiveness of Exubera and its place in therapy
compared with other inhaled insulin delivery systems currently in development remain to be determined. 
Outcomes summary: Exubera is an alternative treatment option for the management of diabetes which provides effective glycemic
control with improved patient satisfaction.
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Core evidence outcomes summary for Exubera (inhaled insulin) in the management of type 1
and type 2 diabetes
Outcome measure Evidence Implications
Patient-oriented evidence
Improved patient satisfaction Clear Improved preference for Exubera compared with subcutaneous insulin
No significant weight gain Clear Similar to or less than subcutaneous insulin
Improvement in quality of life Moderate Improved quality of life with Exubera compared with subcutaneous insulin
Disease-oriented evidence
Effective glycemic control – reduction in HbA1c levels Clear Exubera is as effective as subcutaneous insulin
Incidence of hypoglycemia Moderate Similar to subcutaneous insulin
Reduction in pulmonary function Limited No clinically relevant effect in short term; long-term studies not published
Economic evidence
Cost effectiveness in patients with type 1 and type 2 diabetes No evidence Remains to be determinedScope, aims, and objectives
Effective glycemic control is associated with a reduced risk of
microvascular and macrovascular complications in patients with
diabetes. The inconvenience and poor patient acceptability of
intensive insulin regimens, which may require several injections
per day, has contributed to poor glycemic control in patients with
type 1 or type 2 diabetes. Therefore, alternative routes of insulin
administration to achieve and maintain optimal glycemic control
have been investigated. A dry-powder insulin has been developed
for the pulmonary delivery of insulin by an aerosol device
(Exubera®). The objective of this article is to review the current
evidence for this insulin delivery system in the clinical
management of type 1 and type 2 diabetes. To distinguish this
insulin delivery system from others being developed, it is referred
to as Exubera throughout.
Methods
Literature searches were conducted on January 17–26, 2005, in
the following databases using the search terms “Exubera,”
“pulmonary insulin,” OR “inhaled insulin.” The cut-off date was
from the beginning of the database to the date of the search
unless otherwise stated:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966
to date. Search strategy: “Exubera OR inhaled insulin” limited
to English-language results only
• EMBASE, http://www.datastarweb.com, 1974 to date. Search
strategy: “Exubera OR inhaled insulin” limited to English-
language results only
• Database of Abstracts of Reviews of Effectiveness (DARE),
NHS Economic Evaluations Database (NHSEED), Health
Technology Assessment (HTA), www.york.ac.uk/inst/crd/darehp.htm.
All three databases were searched together. All fields searched 
• National Guideline Clearing House, www.guideline.gov 
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk 
• Cochrane Database of Systematic Reviews (CDSR),
www.cochrane.org/index0.htm. Entire site searched
After removal of duplicates, a total of 206 records were retrieved,
one from DARE and the remainder from PubMed or EMBASE.
Clinical guidelines were also identified from NICE, the European
Diabetes Policy Group (EDPG), and the American Diabetes
Association (ADA). Records were manually reviewed and any animal
studies, in-vitro studies, news articles, general narrative reviews, or
articles which mentioned Exubera but did not discuss clinical trial
data were excluded. The remaining 11 records were included. 
Any identified systematic reviews (including meta analyses),
randomized controlled trials (RCTs), and relevant case studies
were then classified into five classes of evidence based on the
design of the study, with level 1 evidence representing the
strongest level of evidence and level 5 representing the weakest
evidence as summarized in Table 1. One systematic review
was identified. All other articles were of level 2 or level 3
evidence reported as full publications. Publications relating to
pharmacoeconomic evidence with Exubera were not identified.
Thirty-five abstracts from ADA meetings and European
Association for the Study of Diabetes (EASD) meetings
(1998–2003) were identified from a systematic review of these
sources. Twenty-three abstracts were excluded because they
were animal studies (n=1) or were abstracts that duplicated
results from studies which have since been published in full
(n=22). One abstract (level 3 evidence) which detailed results from
a pooled analysis of two multicenter randomized controlled phase
II trials in patients with type 1 and type 2 diabetes was also
excluded due to the availability of significant level 2 evidence
(Cappelleri et al. 2001). 
Abstracts from the 64th Scientific Sessions of the ADA 2004 and
the 40th EASD Meeting 2004 were also searched electronically on
January 26–27, 2005, using the search terms “Exubera” OR
“inhaled insulin.” This yielded 15 records, of which four were
excluded for the following reasons: animal studies (n=2), duplicate
publication of data presented in full papers (n=2) (Table 1). All
abstracts were of level 2 evidence.
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Number of records
Category Full papers Abstracts
Initial search 206 35
records excluded 195 24
records included 11 11
Additional studies identified 01 5
records excluded 0 4
records included 0 11
Search update, new records 12 14
records excluded 9 11
records included 3 3
Level 1 clinical evidence (systematic
review, meta analysis)
10
Level 2 clinical evidence (RCT) 11 25
Level ≥3 clinical evidence 2 0
trials other than RCT 1a 0
case reports 00
pharmacokinetic review 1b 0
Economic evidence 0 0
aFineberg et al. 2005.
bPatton et al. 2004.
For definitions of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review 
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The searches were updated on June 23, 2005. After excluding
duplicates, a total of 12 new records were identified, of which nine
were excluded for the following reasons: general narrative reviews
(n=3), articles that did not mention Exubera (n=5), animal study
(n=1). Three articles remained, and were included (Table 1).
Abstracts from the 65th Scientific Sessions of the ADA 2005
(http://scientificsessions.diabetes.org) were also searched
electronically on June 29, 2005. This yielded 14 records, of which
11 were excluded for the following reasons: did not refer to
Exubera (n=9), animal studies (n=2) (Table 1). All abstracts were of
level 2 evidence.
Disease overview 
The diabetes epidemic
It is estimated that there are currently approximately 194 million
people with diabetes worldwide and the prevalence is projected
to exceed 333 million by 2025 (IDF 2005). Type 1 diabetes may
account for 5–10% of all diagnosed cases of diabetes and usually
affects children and young adults, although onset may occur at
any age (ADA 2005a). In comparison, type 2 diabetes accounts
for over 90% of diabetes cases and is associated with age,
obesity, family history of diabetes, impaired glucose metabolism,
physical inactivity, and race/ethnicity. The increasing prevalence
of type 2 diabetes in children and adolescents is fast being
recognized as a global health problem (Pinhas-Hamiel & Zeitler
2005).
Consequences of inadequate glycemic control
A recent report by the American Association of Clinical
Endocrinologists (AACE) highlighted that 67% of individuals with
type 2 diabetes did not have adequately controlled blood glucose
levels (AACE 2005). Uncontrolled diabetes may contribute to
increased rates of macrovascular and microvascular diabetic
complications. Indeed people with diabetes are two to four times
more likely to develop cardiovascular disease and have a greater
risk of heart attack or stroke than individuals without diabetes (IDF
2005). Diabetes is also the leading cause of end-stage renal
disease, accounting for 44% of new cases and is the leading
cause of blindness in the Western world (CDC 2003). These
complications place a huge burden on healthcare services. It is
estimated that the total direct and indirect expenditure for
diabetes in the US alone in 2002 was $US132 billion (Hogan et al.
2003). A recent meta analysis of prospective cohort studies in
patients with diabetes has also suggested that hyperglycemia is
associated with an increased risk of cardiovascular disease
(Selvin et al. 2004). 
The UK Prospective Diabetes Study (UKPDS) and the Diabetes
Control and Complications Trial (DCCT) demonstrated that the
risk of developing and the progression of microvascular
complications are substantially reduced with intensive blood
glucose control (HbA1c approximately 7%) in both type 2 diabetes
(UKPDS 1998a,b) and type 1 diabetes (DCCT 1993). In general,
for every 1% reduction in HbA1c, the risk of developing
microvascular diabetic complications is reduced by 40% (CDC
2003). The DCCT study showed that intensive insulin therapy
(administration of insulin three or more times daily by injection or
an external pump) decreased the frequency and severity of
microvascular and neurologic complications compared to
conventional insulin (DCCT 1993). The occurrence of
microalbuminuria was reduced by 39% and albuminuria and
clinical neuropathy were reduced by 54% and 60%, respectively.
However, this intensive therapy was associated with a two- to
three-fold increase in severe hypoglycemia. Furthermore, the
UKPDS 33 study demonstrated that weight gain was significantly
higher (mean + 2.9 kg) in patients with type 2 diabetes receiving
intensive blood glucose control with sulfonylureas or insulin
compared with conventional treatment with diet (P<0.001)
(UKPDS 1998a). A further study in Japanese patients with type 2
diabetes demonstrated that intensive glycemic control by multiple
insulin injection therapy delayed the onset and progression of
diabetic retinopathy, nephropathy, and neuropathy more
effectively than conventional insulin therapy (Ohkubo et al. 1995).
Current therapy options 
Type 1 diabetes
Type 1 diabetes develops when the body’s immune system
destroys pancreatic beta cells and the individual is unable to
produce insulin to control blood glucose levels. Therefore, it is
essential that patients with type 1 diabetes receive insulin. Several
types of human insulin and insulin analogs are currently available
(Table 2). Insulin may be delivered by subcutaneous, multiple
injections via a syringe or a pen with needle and cartridge, or via
an insulin pump (ADA 2004). Insulin pumps are small devices
(about the size of a pager), containing a reservoir of rapid-acting
insulin, which are programmed to deliver a constant flow of insulin
into the patient via a needle or cannula.
Rapid-acting insulin analogs are generally injected with a meal and
have a rapid onset and a short duration of action, so there is less
chance of hypoglycemia. These are generally considered the most
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Rapid-acting insulin analogs
Insulin lispro (Humalog®)
Insulin aspart analog (Novolog® USA; NovoRapid® Europe)
Insulin glulisine (Apidra™)
Short-acting insulin
Human insulin (Humulin R®/Novolin R®)
Intermediate-acting insulin
Human NPH (Humulin N®/Novolin N®)
Lente
Long-acting insulin
Insulin glargine analog (Lantus®)
Human ultralente (Humulin U Ultralente®)
Insulin detemir (Levemir®) – not yet approved in the USA
Table 2 | Commonly used human and analog insulins (adapted
from ADA 2005b)
 appropriate type of insulin for mealtime use. Short-acting insulins
may also be used at mealtimes. However, their time to onset and
duration of action is greater than that of the rapid-acting analogs.
Long-acting insulins are the best options for basal control of blood
glucose and are generally used in combination with either rapid-
acting or short-acting insulin. Premixed insulins are also available
which contain a combination of intermediate-acting and either
rapid-acting or short-acting insulins. These premixed insulins are
generally available as pre-filled insulin pens which improve the
accuracy of insulin administration and adherence. 
One of the major disadvantages of insulin use is the occurrence
of hypoglycemia resulting from an imbalance of insulin use, and
physical activity and/or calorie consumption. 
Type 2 diabetes
Initially, patients with type 2 diabetes may be able to control their
blood glucose levels with diet and exercise alone or with
antihyperglycemic drug monotherapy. However, many patients
will progress to require additional therapies (combination oral
agents and/or insulin). Currently, there are several classes of oral
antidiabetic medication available which may be used as a
monotherapy or in combination (Table 3). Most of the commonly
used oral antidiabetics are only able to reduce HbA1c by
approximately 1%. This reduction is not sufficient for patients
who have HbA1c levels much greater than the recommended
target. Furthermore, long-term glycemic control is difficult to
sustain with oral antidiabetic agents and many patients
additionally require insulin therapy.
New classes of noninsulin diabetic drugs have entered the market
to address the need for long-term glycemic control in patients
with type 2 diabetes. These include the glucagon-like peptide-1
(GLP-1) agonist exenatide (Byetta®), and a synthetic analog of
human amylin called pramlintide acetate (Symlin®) which was
approved by the Food and Drug Administration (FDA) in March
2005. The dipeptidyl peptidase-4 (DPP-4) inhibitors are also soon
expected to enter the market.
GLP-1 analogs
GLP-1 is an incretin hormone which is secreted from endocrine
cells located in the intestinal mucosa, and acts to enhance meal-
induced insulin secretion. GLP-1 analogs are injectable and it is
expected that they will be used following the failure of oral
antidiabetic agents in patients who are reluctant to use insulin.
The GLP-1 analog exenatide is the first in a new class of diabetes
treatment called incretin mimetics to be approved by the FDA
(June 2005). It is approved as an adjunctive therapy in patients
with type 2 diabetes who have not achieved adequate control on
metformin and/or a sulfonylurea. Liraglutide, a long-acting
derivative of GLP-1 which will be administered by injection once
a day, is expected to be launched in 2007.
DPP-4 inhibitors
The DPP-4 inhibitors inhibit the enzyme responsible for the
breakdown of GLP-1 (Nielsen 2005). In animal studies, DPP-4
inhibitors have been reported to suppress DPP-4 activity by up to
90% and to delay the onset of hyperglycemia (Nielsen 2005).
Several DPP-4 inhibitors are currently in development including
LAF-237 (Novartis) and MK-431 (Merck) (Barlocco 2004). These
inhibitors are currently in phase III trials and the launch of LAF-237
and MK-431 are expected in 2007 and 2009, respectively. In
contrast to the GLP-1 analogs, these agents will be available as
oral formulations which should increase patient acceptability and
compliance.
Current treatment guidelines
Recent US, European, and UK guidelines for type 2 diabetes
recommend glycemic targets with an HbA1c target range below
6.5–7.5% (EDPG 1999; NICE 2002; ADA 2005c). The ADA
guidelines also recommend considering a target of <6% in
individual patients (ADA 2005c). The risks and benefits of HbA1c
levels below 6% are currently being evaluated by the ongoing
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
study in patients with type 2 diabetes.
Current NICE guidelines (due to be reviewed in September 2005)
recommend that insulin therapy should be offered to diabetic
patients with inadequate blood glucose control receiving
optimized oral antidiabetic agents (NICE 2002). Furthermore,
EDPG guidelines recommend that insulin therapy is initiated when
HbA1c has deteriorated to >7.5% after maximum attention to
dietary control and oral glucose-lowering therapy (EDPG 1999).
An algorithm for the treatment of type 2 diabetes mellitus
suggests that insulin should be reserved for patients who fail to
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Class and mechanism of action Drug
Biguanides
Reduce hepatic glucose production Metformin
Insulin secretagogs (sulfonylureas) 
Stimulate the islet β cells of the
pancreas to produce more insulin
first generation Chlorpropamide, tolazamide
second generation Glibenclamide (glyburide), glipizide,
glimepiride, gliclazide, gliquidone 
Rapid-acting insulin secretagogs
(meglitinides)
Stimulate glucose-mediated insulin
secretion
Nateglinide, repaglinide
α-glucosidase inhibitors
Delay digestion and absorption of
intestinal carbohydrate
Acarbose, miglitol
Thiazolidinediones (glitazones)
Peroxisome proliferator-activated
receptor-γ agonists: insulin sensitizer
improving insulin action and reducing
insulin resistance
Rosiglitazone, pioglitazone
Table 3 | Oral antidiabetic medications used for the treatment
of type 2 diabetes93
adequately respond to a combination of oral antidiabetic agents
(Krentz & Bailey 2005). However, Krentz and Bailey (2005) suggest
that prescribing decisions often appear to be made on subjective
grounds such as familiarity with a particular drug which may
explain regional differences in prescribing.
Unmet needs 
To avoid the development of complications and reduce morbidity
and mortality in patients with diabetes, tight glycemic control is of
great importance. Insulin therapy is central to the treatment of
patients with type 1 diabetes. In contrast, the progressive
decrease in beta-cell function in the pathogenesis of type 2
diabetes means that many patients will eventually fail on oral
antidiabetic agents and will require insulin. It is well known in
routine clinical practice that the majority of patients fail to achieve
optimal glycemic control. Data from the National Health and
Nutrition Examination Survey (NHANES) III demonstrated that
from 1988 to 2000 a decrease in glycemic control was observed
among US adults diagnosed with type 2 diabetes (Koro et al.
2004). The proportion of patients with HbA1c levels <7% declined
from 44.5% in the period 1988–1994 to 35.8% between 1999 and
2000. The use of insulin alone also decreased from 24.2% to
16.4% in these periods. There is reluctance by patients and
physicians to treat type 2 diabetes with insulin despite its ability
to achieve tight glycemic control. Healthcare providers often
delay the initiation and intensification of insulin therapy in patients
with type 2 diabetes until after the failure of multiple oral agents.
This reluctance to initiate insulin therapy is partly due to the
burden of multiple daily injections which are associated with poor
patient compliance, particularly in those patients with a phobia of
needles, and a fear of causing hypoglycemia or weight gain
(Korytkowski 2002). Therefore, alternative insulin delivery systems
are required to improve patient and physician acceptability,
adherence with insulin therapy, and thus improve the
management of the disease. However, the mode of administration
may not be the only issue. Many patients may perceive insulin per
se as a “failure” in themselves or their health professional and that
their diabetes is now “severe.”
New methods for the delivery of insulin must balance improved
patient acceptability, convenience and quality of life with
achievement of therapeutic drug levels that are at least as
effective as traditional subcutaneous formulations on diabetic
outcomes such as blood glucose and HbA1c, without increasing
the risk of hypoglycemic episodes or weight gain. It is expected
that improved glucose control achieved by better adherence to
insulin regimens will reduce the development of complications
commonly associated with diabetes.
Advances in syringe and needle technology and the use of insulin
pens and pumps have improved the accuracy and convenience of
insulin administration. Despite the relative success of these
devices, several different routes of administration have been
investigated including the transdermal, intranasal, oral, buccal,
and pulmonary routes (Owens et al. 2003; Cefalu 2004). Limited
success has been achieved with intranasal, oral, and transdermal
insulin delivery. Due to the large size of the insulin molecule, nasal
and transdermal delivery is inadequate and requires penetration
enhancers which pose safety concerns (Owens et al. 2003; Cefalu
2004). Therefore, these modes of delivery would be more suited
to basal administration of insulin. Oral enteric insulin is broken
down by digestive enzymes and has limited bioavailability (Cefalu
2004). A buccal system (Oralin) delivering a liquid formulation of
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Inhaled insulin system Manufacturer Delivery system Phase 
Exubera® Pfizer; Sanofi-Aventis Group and
Nektar Therapeutics
Fine dry-powder insulin
Air-assisted mechanism disperses the
powder from single-dose blisters into
a respirable cloud captured in a
holding chamber
Phase III
Filed for approval in Europe
Recommended for approval in USA
AERx® insulin Diabetes Management
System (iDMS)
Aradigm and Novo Nordisk Aqueous mist inhaler
Single-use insulin strips with a hand-
held, breath-activated,
microprocessor-controlled device
Phase III
Advanced Inhalation Research
(AIR) System
Alkermes and Eli Lilly & Company Breath-activated dry-powder inhaler Entering phase III
Technosphere Insulin System MannKind Corporation Proprietary dry-powder technosphere
formulation
Inhaled using MedTone® inhaler
Phase III
Aerodose™ Aerogen and Disetronic Medical
Systems
Liquid insulin formulation (Humalin I™
500 units)
Aerosol delivered by a breath-
activated delivery device
Phase II
Inhaled insulin Kos Pharmaceuticals Inc. Dry crystals propellant inhaler Phase II
Bio-Air BioSante Pharmaceuticals Coated dry particles Preclinical
Table 4 | Inhaled insulin products: delivery system and trial phase
 insulin as a fine spray via the Generex Rapid Mist™ device has
been developed by Generex Biotechnology. Limited data in
patients with type 2 diabetes have demonstrated that Oralin may
be used instead of meal-time insulin injections (Guevara-Aguirre
et al. 2004a,b).
The lungs have a large surface area, highly permeable membrane,
and rich blood perfusion offering great potential for the delivery of
polypeptide drugs such as insulin across the alveolar wall. Several
inhaled insulin products have been successful in controlling blood
glucose levels and three products are currently in phase III clinical
trials (Table 4). Comparisons between these inhaled insulin delivery
systems are needed to determine the advantages and
disadvantages of each system including their relative convenience
and ease of use.
Of these different inhaled insulin products, Exubera is the furthest
along in development. Exubera is a fine dry-powder (particle size
1–5 µm) insulin formulation jointly developed by Pfizer and Sanofi-
Aventis Group. The insulin formulation developed by Nektar
Therapeutics is packaged into blisters containing either 1 or 3 mg
of insulin and made up to a total weight of 5 mg with mannitol,
glycine, and sodium citrate. Higher doses are achieved with
further inhalation of 1 or 3 mg blisters. Nektar Therapeutics
developed both the insulin blisters and a hand-held inhaler
device, which converts the powder particles into an aerosol
cloud. This noninvasive, pulmonary inhalation system delivers
insulin into the systemic circulation via the lung alveoli by
transcytosis. No power source or propellants are used and the
clear chamber ensures that the patient knows when all the insulin
has been inhaled to allow accurate dosing. However, some
patients may question the convenience of the chamber with
regards to its portability. 
The AERx® iDMS delivery device includes a breath-guidance
system that only delivers drug to the lung when breathing is
correct (Mandal 2005). This device also features a data-
downloading system, facilitating the review of dose administration
data and breathing technique. This provides clinicians with
information about patient dosing regimens and compliance
(Cramer et al. 2004). In comparison, the Technosphere insulin
system used a commercially available asthma inhaler for the
proof-of-concept study (Steiner et al. 2002).
Clinical evidence with Exubera
A number of patient- and disease-oriented outcomes have been
evaluated with Exubera that reflect its potential role in the
management of diabetes. Fundamentally, the formulation must
demonstrate that therapeutic levels of insulin can be achieved,
which have an effect on blood measures of glucose and which do
not raise the risk of hypoglycemia. From a patient perspective, the
formulation needs to be acceptable to patients and ideally more
convenient than alternative methods of delivery. 
Achievement of insulin levels
Studies assessing the pharmacokinetics of Exubera in healthy
volunteers and in patients with type 2 diabetes have shown that
Exubera is rapidly absorbed, with insulin concentrations peaking
earlier and decreasing more rapidly compared with subcutaneous
regular insulin (Patton et al. 2004). Furthermore, the onset of action
(time to maximal effect) of Exubera has been shown to be at least
as fast as the subcutaneously injected rapid-acting insulin
analog insulin lispro in healthy volunteers (143 min versus
137 min) (Rave et al. 2005). The duration of action, as determined by
time to late half-maximal effect, was longer with Exubera than lispro
(387min versus 313 min). These characteristics suggest that Exubera
provides an alternative therapy for meal-time glucose control.
Blood glucose control
The efficacy of Exubera was primarily assessed by equivalence
studies comparing glycemic control with subcutaneous insulin.
Reduction in HbA1c levels and the proportion of patients who met
treatment guideline targets for HbA1c (i.e. below 6.5–7.5%) were
the main outcomes for efficacy. 
Strong level 1 evidence from a systematic review of small, short-
term, proof of concept phase II studies in patients with type 1
diabetes (3 studies) and type 2 diabetes (3 studies) showed
similar HbA1c reductions in patients randomized to inhaled insulin
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Study Treatment group Outcome
Mean reduction in HbA1c (%) % patients with HbA1c <7% 
Skyler et al. 2005 Exubera (premeal) plus morning and evening NPH insulin
(n=163)
0.3 23.3
Regular s.c. insulin (premeal) plus morning and evening
NPH insulin (n=165)
0.1 22
Quattrin et al. 2004 Exubera (premeal) plus a single bedtime ultralente s.c.
injection (n=170)
0.2 15.9
Two to three s.c. injections of regular and NPH insulin
(n=164)
0.4 15.5
s.c., subcutaneous.
Table 5 | Level 2 evidence of blood glucose control in patients with type 1 diabetes achieved with Exubera compared with
conventional insulin regimens. Both studies were open-label, randomized, multicenter design lasting 24 weeks
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plus subcutaneous ultralente compared with a control group who
received their former subcutaneous insulin regimen (Cefalu et al.
2001; Skyler et al. 2001; Royle et al. 2003). A further proof of
concept superiority study also showed that glycemic control
could be improved in insulin-naïve patients with type 2 diabetes
and suboptimal glycemic control by the addition of Exubera to
oral antidiabetic agents compared to oral antidiabetic
monotherapy (Weiss et al. 2003).
These observations are supported by evidence from two open-
label, randomized phase III clinical studies of 6 months’ duration
which demonstrates that Exubera provides glycemic control
comparable to that with conventional insulin regimens in patients
with type 1 diabetes (Quattrin et al. 2004; Skyler et al. 2005)
(Table 5). Furthermore, a study in 226 patients with type 1
diabetes has shown that Exubera provides glycemic control
similar to that of a subcutaneous short-acting insulin over a 12-
week period (Dumas et al. 2005a).
Results from three open-label, randomized, parallel-group,
multicenter, phase III clinical trials in patients with type 2 diabetes
have also demonstrated comparable reductions in HbA1c
between Exubera and conventional subcutaneous insulin
regimens (Hollander et al. 2004). Furthermore, superiority studies
showed that Exubera either alone or in combination with oral
antidiabetic regimens demonstrated improved glycemic control
compared with oral agent monotherapy (Cefalu 2002; Rosenstock
2002; Bergenstal 2003; DeFronzo 2003; Barnett 2004; Dreyer
2004) (Table 6). Moreover, more patients with type 2 diabetes who
were treated with inhaled insulin achieved the ADA and EDPG
(IDF Region) targets for HbA1c levels compared with other
regimens (Table 6) (Bergenstal 2004). 
In all the phase III trials comparing Exubera with subcutaneous
insulin, the control groups had two or more insulin injections daily
of a soluble insulin, in addition to a basal insulin. However, only
one study (Skyler et al. 2005) used the same basal insulin in both
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Study Treatment group Study design Outcome
Mean reduction
in HbA1c (%)
% patients with
HbA1c <7% (ADA)
% patients with
HbA1c <6.5%
(EDPG)
Hollander et al. 2004 Exubera (premeal) plus bedtime
dose of ultralente (n=149)
24 weeks; patients previously
treated with insulin
0.7 46.9 28.7
≥2 daily injections of s.c. insulin
(mixed regular/NPH insulin; n=150)
0.6 31.7 17.2
Rosenstock et al. 2002;
Cefalu 2002
Exubera (premeal) monotherapy
(n=105)
12 weeks; patients failing on
combination oral antidiabetic
agents (sulfonylurea or repaglinide,
plus metformin or a glitazone)
1.4 16.7 12.2
Exubera plus existing oral
antidiabetic medication (n=102)
1.9 32 7.8
Continued oral antidiabetic
medication (n=102)
0.2 1 0
Bergenstal et al. 2003;
DeFronzo 2003
Exubera (premeal) monotherapy
(n=76)
12 weeks; patients failing on diet
and exercise alone
2.3 44 28
Rosiglitazone 4 mg twice daily
(n=69)
1.4 17.9 7.5
Barnett 2004 Adjunctive Exubera (n=471) Open-label, 24 weeks extended to
52 weeks; patients poorly
controlled by metformin or
sulfonylurea (HbA1c ≥8%)
2.2% (week 24)
2% (week 52)
ND ND
Additional oral antidiabetic
(metformin or glibenclamide)
(n=441)
2.2% (week 24)
1.8% (week 52)
ND ND
Dreyer 2004 Adjunctive Exubera (n=471) 24 weeks, extended to 104 weeks;
patients poorly controlled by
metformin or sulfonylurea 
(HbA1c ≥8%)
1.9% ND ND
Additional oral antidiabetic
(metformin or glibenclamide)
(n=441)
1.5% ND ND
ADA, American Diabetes Association; EDPG, European Diabetes Policy Group; ND, data not provided; s.c., subcutaneous. 
Table 6 | Level 2 evidence of blood glucose control in patients with type 2 diabetes achieved with Exubera compared with
conventional insulin regimens. All studies were open-label, randomized, parallel-group, multicenter design
 treatment groups, and none of the studies used a short-acting
insulin analog.
Patient satisfaction 
Eight clinical trials evaluated treatment satisfaction and quality of
life compared with subcutaneous insulin or oral antidiabetic
therapy in both patients with type 1 diabetes (Gerber et al. 2001;
Testa et al. 2001a,b; Quattrin et al. 2004) and type 2 diabetes
(Simonson et al. 2001, 2004; Cappelleri et al. 2002; Testa et al.
2002, 2004a,b; Hollander et al. 2004) (Table 7). 
In general, inhaled insulin had a greater acceptance relating to
convenience and ease of use. For obvious practical reasons,
these studies were unblinded to their intervention which could
potentially affect the outcomes. Furthermore, in these studies
patients used syringes and standard needles which are less
convenient and more painful than pen-injector devices. The
majority of these studies were conducted in the USA, where
insulin pen-injector devices are not approved. Therefore, further
studies are required to compare treatment satisfaction with
inhaled insulin versus pen-injector devices. Patient satisfaction
was assessed using a self-administered satisfaction
questionnaire. The Patient Satisfaction with Insulin Therapy (PSIT)
questionnaire was developed by the manufacturer of Exubera to
assess novel forms of insulin delivery such as inhaled insulin
(Cappelleri et al. 2000) and was used in phase II studies (Gerber
et al. 2001; Cappelleri et al. 2002). The self-administered Diabetes
Quality of Life and Treatment Satisfaction Questionnaire was
independently developed by Phase V Technologies and was used
for all phase III studies. 
A pooled analysis of the patient satisfaction data from the two
12-week parent studies in patients with type 1 diabetes (n=70) or
type 2 diabetes (n=51) receiving Exubera or subcutaneous insulin
and 1-year extension studies was performed (Rosenstock et al.
2004). Of the patients who received Exubera, 85% (51 of 60) chose
to continue treatment compared with 21% (13 of 61) of patients
receiving subcutaneous insulin. In addition, 75% (46 of 61) of
patients switched from subcutaneous insulin to Exubera compared
with 13% (8 of 60) switching from Exubera to subcutaneous insulin.
At 1 year, greater improvements in patient satisfaction were
observed in the Exubera group compared with the subcutaneous
group for overall satisfaction (37.9% vs 3.1%; P<0.01) and ease of
use (43.2% vs –0.9%; P<0.01). However, it should be noted that the
sample size at 1 year was greater for the Exubera group compared
with the subcutaneous insulin group (95 patients vs 17 patients,
respectively) because most of the patients originally in the
subcutaneous insulin group switched to Exubera therapy during the
study. Patients who switched from inhaled insulin to subcutaneous
insulin showed a trend towards worsening satisfaction scores. 
In addition, a study of theoretical treatment choices in 779
patients with type 2 diabetes failing to achieve target glycemic
control on diet and/or oral antidiabetic therapy demonstrated that
patients offered insulin as a treatment option significantly
increased the proportion of patients who would theoretically
choose insulin (Freemantle et al. 2005).
Hypoglycemia
Overall evidence indicates that the total number of hypoglycemic
episodes with inhaled insulin and subcutaneous insulin is similar,
with no increase in the incidence or severity.
Two 6-month studies demonstrated that the risk of overall
hypoglycemia was lower in the Exubera group compared with the
subcutaneous insulin group for patients with type 1 diabetes
(8.6 vs 9 events/subject month; risk ratio 0.96) (Quattrin et al.
2004) and type 2 diabetes (1.4 vs 1.57 events/subject month; risk
ratio 0.89) (Hollander et al. 2004). One 3-month study in patients
with type 2 diabetes reported a higher rate of hypoglycemic
epidodes with Exubera (1.3 events/patient-month) which was not
surprising as Exubera was compared with oral antidiabetic
therapy alone (0.1 events/patient-month) (Rosenstock 2002).
However, a 3-month study in patients with type 1 diabetes
reported a higher rate of hypoglycemia with Exubera
(6.8 events/subject-month) compared with subcutaneous short-
acting insulin (5.5 events/subject-month) (Dumas et al. 2005a).
The incidence of severe hypoglycemic events was low and not
significantly different in patients receiving either Exubera or
subcutaneous insulin in patients with type 1 diabetes
(5.5 events/100 subject months vs 4.7 events/100 subject
months) (Quattrin et al. 2004) or in patients with type 2 diabetes
(0.5 events/100 subject months vs 0.1 events/100 subject
months, respectively) (Hollander et al. 2004). 
Weight gain
Insulin therapy is often associated with weight gain, particularly in
patients with type 2 diabetes. Two 6-month studies have reported
that treatment with Exubera was not associated with a significant
weight gain (Hollander et al. 2004; Quattrin et al. 2004). In patients
with type 2 diabetes treated with Exubera, mean body weight
after 24 weeks remained stable at 90.5 kg, compared with a mean
increase of 1.4 kg to 90.6 kg in body weight in the subcutaneous
treatment group by week 24 (Hollander et al. 2004). Similar results
occurred in patients with type 1 diabetes, with a smaller increase
in body weight at week 24 in Exubera-treated patients compared
with those receiving subcutaneous insulin (0.9 kg vs 1.5 kg)
(Quattrin et al. 2004). 
Tolerability 
Level 2 evidence from two RCTs in patients with type 1 diabetes
or type 2 diabetes has demonstrated that Exubera is well
tolerated (Hollander et al. 2004; Quattrin et al. 2004). In these two
studies, adverse events were comparable between treatment
groups. Individuals treated with Exubera may develop an increase
in serum insulin antibody levels, although these levels were not
associated with a significant clinical change (Heise et al. 2004a,b;
Fineberg et al. 2005). A meta analysis of insulin antibody data
from Exubera trials demonstrated that there were no correlations
between antibody binding and glycemic control, insulin dose
requirements, hypoglycemic events, or pulmonary function
(Fineberg et al. 2005). Furthermore, a 24-week study in patients
with type 1 diabetes and results from three phase III trials in
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Reference Treatment group Study design  Outcomes
Type 1 diabetes
Gerber et al.
2001
Exubera (premeal) plus bedtime
dose of ultralente (n=35)
s.c. insulin (n=34)
Open label; 12 weeks; PSIT
questionnaire at baseline and
week 12
Overall satisfaction was significantly greater with Exubera than with
s.c. insulin (35.1% vs 10.6%; P<0.01)
Improved convenience/ease of use with Exubera compared with s.c.
insulin (41.3% vs 11.2%; P<0.01)
Quattrin et al.
2004;
Testa et al.
2001a;
Su et al. 2002
Exubera (premeal) plus bedtime
dose of ultralente (n=170)
s.c. insulin (n=164)
Open label; parallel group; 24
weeks; self-administered Diabetes
QOL and Treatment Satisfaction
Questionnaire at weeks –4, –1, 6,
12, 20, and 24
Mean overall satisfaction score improved significantly for the
Exubera group (P<0.001) and decreased significantly with s.c. insulin
(P<0.05) (no scores given)
Overall QOL scale showed more favorable improvements for the
Exubera group versus the s.c. insulin group (P<0.05)
Testa et al.
2001b
Exubera (premeal) plus NPH
insulin twice daily (n=162)
Regular insulin (premeal) plus
NPH insulin twice daily (n=165)
QOL and satisfaction questionnaire
completed at baseline and 6, 12,
20, and 24 weeks
Overall satisfaction score improved substantially more for Exubera
(from 62.1 to 74.5) compared with regular insulin (from 62.8 to 64.3)
(P<0.0001)
The overall QOL scale and subscales of behavioral and emotional
control, general and hyperglycemic symptom distress, overall
cognition, mental acuity, and awareness improved more favorably
with Exubera compared with regular insulin (all P<0.01–0.05)
Type 2 diabetes
Cappelleri et al.
2002
Exubera (premeal) plus bedtime
dose of ultralente (n=26)
s.c. insulin (n=25)
Open label; 12 weeks; PSIT
questionnaire
Overall satisfaction was significantly greater with Exubera than with
s.c. insulin (31% vs 13%; P<0.05)
Improvements in overall satisfaction were positively correlated with
improvements in HbA1c (r=0.30; P<0.05)
Simonson et al.
2001
Exubera (premeal) monotherapy
Remain on current oral
antidiabetic
Exubera (premeal) plus current
oral antidiabetic
309 patients suboptimally controlled
on a sulfonylurea plus either
metformin or a thiazolidinedione
Patient satisfaction questionnaires
completed at baseline and 6 and 12
weeks after randomization
Proportion of patients receiving Exubera monotherapy or Exubera in
combination with oral antidiabetics who preferred the inhaler to their
previous combination of oral antidiabetic agents for better glucose
control (92%), ease of dose adjustment (79%), overall preference
(74%), feeling better about themselves (74%)
Patients preferred oral agents for use in public (81%), convenience
(69%), ease (63%), and flexibility (59%)
Testa et al.
2004a,b
Exubera (premeal) (n=222) 
Metformin (n=201) 
24 weeks; patients poorly controlled
on sulfonylurea; randomization
stratified according to baseline
HbA1c levels (low=8–9.5%;
high=>9.5–12%); self-administered
questionnaires were completed at
baseline (week 0) and at weeks 10,
18, 24, and exit
Improvements in HbA1c were positively correlated with
improvements in overall satisfaction (r=0.254; P<0.0001)
Overall QOL improved similarly for Exubera (0.24±0.09, P=0.01) and
metformin (0.21±0.11, P=0.06)
Overall satisfaction (scaled 1–100) substantially improved for both
Exubera (from 62.1 to 76.1, P=0.0001) and metformin (from 63.1 to
74.1, P=0.0001)
High HbA1c stratum: overall satisfaction was 42% greater for
Exubera (from 60.2 to 77.1) than metformin (from 61.2 to 73.2)
(P=0.02)
Simonson et al.
2004; Testa et al.
2004c
Exubera (premeal) (n=239)
Glibenclamide (n=231)
24 weeks; patients poorly controlled
on metformin monotherapy;
randomization stratified according
to baseline HbA1c levels
(low=8–9.5%; high=>9.5–12%); self-
administered questionnaires were
completed at baseline (week 0) and
at weeks 10, 18, 24, and exit
High HbA1c stratum: overall QOL score more favorable for Exubera
(468±5) vs glibenclamide (454±5) (P=0.04)
Low HbA1c stratum: no significant difference in overall QOL score
between treatment groups (Exubera 457±4 vs glibenclamide 467±5;
P=0.08)
Similar improvements in treatment satisfaction for both treatment
groups
Improvements in HbA1c were positively correlated with
improvements in general perceived health (r=0.11; P=0.03), general
health status (r=0.12; P=0.014), and convenience (r=0.15; P=0.003)
Hollander et al.
2004; Testa et al.
2002
Exubera (premeal) plus bedtime
dose of ultralente (n=149)
s.c. insulin (n=150)
Open label; parallel group; 24
weeks; self-administered Diabetes
QOL and Treatment Satisfaction
Questionnaire at baseline and
weeks 6,12, 20, and 24
Mean overall satisfaction score improved significantly for the
Exubera group (P<0.0001) and worsened slightly with s.c. insulin
(no scores given)
Overall QOL scale showed more favorable improvements for the
Exubera group versus the s.c. insulin group (P<0.05)
PSIT, Patient Satisfaction with Insulin Therapy Questionnaire; QOL, quality of life; s.c., subcutaneous.
Table 7 | Level 2 evidence demonstrating patient satisfaction and quality of life ratings in patients treated with Exubera compared
with subcutaneous insulin or oral antidiabetic agentspatients with type 2 diabetes over a 2-year period provided
further evidence that the antibody response did not correlate with
pulmonary function changes or changes in glycemic control
(Cefalu et al. 2005; Dumas et al. 2005b). 
There have been some concerns regarding the safety of inhaled
preparations and whether they compromise lung capacity or
damage lung tissue with long-term use. 
Mild to moderate cough was more frequent in the inhaled insulin
group (21–30.9% of Exubera-treated patients vs 2–7.8% of
subcutaneous insulin-treated patients) and decreased with
increased exposure. Mean changes in pulmonary function were
comparable between patients treated with subcutaneous insulin
and Exubera-treated patients (Hollander et al. 2004; Quattrin et al.
2004) except for a greater decrease in carbon monoxide diffusing
capacity (DLco) in the Exubera group in patients with type 1
diabetes (Quattrin et al. 2004). This decrease was not associated
with any significant clinical or laboratory change.
Evidence in abstract form is available from open-label, 24-week
studies which were extended with the objective of assessing
pulmonary safety after long-term use of Exubera. A pooled
analysis of two 1-year open-label studies involving 627 patients
with type 2 diabetes showed that patients who added Exubera to
their treatment regimen experienced no clinically important effect
on pulmonary function compared with patients treated with oral
agents alone (Barnett 2004). This study was further extended to
104 weeks and demonstrated that the treatment group
differences in pulmonary function as assessed by forced
expiratory volume in 1 s (FEV1) and DLco were small, not clinically
relevant, and did not progress over the 2-year study period
(Dreyer 2004). Furthermore, the treatment differences in
pulmonary function reversed after discontinuation of Exubera
during the washout phase (week +12 after 104 weeks of therapy)
(Dreyer 2004). An additional analysis of 4-year Exubera data
further supported these findings in patients with type 1 or type 2
diabetes (Skyler 2004a,b). 
Resource utilization 
There is no published evidence of the cost effectiveness of
Exubera, and no decision has yet been reached on its unit cost.
Greater amounts of inhaled insulin are required to produce similar
efficacy to injectable formulations because of the reduced
bioavailability by this route. Therefore, acquisition costs may be
higher for all inhaled insulin delivery systems due to the amount
of “wastage.” However, it is important to consider the relatively
small contribution drug therapy makes to the overall cost of
managing diabetes, and the proportionately greater costs of
illness and its complications that may be offset if the disease is
managed effectively.
Complications of diabetes such as blindness, heart disease, and
kidney failure place a huge burden on healthcare services. The
IDF estimate that diabetes accounts for between 5 and 10% of a
nation’s health budget. Moreover, the European Cost Of Diabetes
in Europe – type 2 (CODE-2) study estimated that three times the
healthcare resources are spent on treating diabetes complications
compared with that spent on controlling diabetes before the onset
of complications. This study estimated that the average yearly
cost per patient was €2834. Of these costs, hospitalizations
accounted for the greatest proportion (55%, range 30–65%)
totalling €15.9 billion. In contrast, drug costs for managing type 2
diabetes were relatively low, with antidiabetic drugs and insulin
accounting for only 7% of the total healthcare costs for type 2
diabetes (Jonsson 2002). Therefore, the human and economic
costs of diabetes could be reduced by preventing the onset of
these complications. 
There is strong evidence that good glycemic control with intensive
insulin therapy can substantially reduce the risk of and slow the
progression of these complications (DCCT 1993; Ohkubo et al.
1995; UKPDS 1998b). Studies have shown that HbA1c levels are
directly linked to healthcare costs with even a 1% increase in
HbA1c levels increasing healthcare costs (Gilmer et al. 1997; Gray
et al. 2000; Clarke et al. 2001). Therefore, it would be expected
that noncompliance with insulin therapy would lead to poor
glycemic control and thereby have an adverse impact on the
development of diabetes complications and increase healthcare
costs. This highlights the need for alternative therapies for the
treatment of diabetes which improve patient adherence and
hence glycemic control. Controlling blood glucose should have a
beneficial effect on costs, but in order to determine Exubera’s
place in therapy, comparisons with other inhaled devices and
additional patient preference data are needed.
Patient group/population 
Level 2 evidence demonstrates the safety and efficacy of
Exubera in patients with type 1 and type 2 diabetes who are
otherwise healthy, suggesting that it could have a role in the
general treatment of patients with uncomplicated disease.
Evidence with inhaled insulin is limited in patients with
concomitant diseases. Key factors which may influence the
efficiency of inhaled insulin delivery include the patients’ age (i.e.
pediatric and elderly), ability to operate the device, smoking,
asthma, exercise, and the presence of lung disease such as
chronic obstructive pulmonary disease or chronic bronchitis.
Limited evidence from a small number of studies with AERx
insulin Diabetes Management System (iDMS) in smokers,
patients with asthma, and the elderly is available, some of which
may be applicable to Exubera. However, stronger evidence is
required to clearly establish the efficacy and safety of Exubera in
these patient groups.
Smoking
Smoking appears to greatly enhance insulin absorption by
increasing the permeability of the alveolar–capillary barrier
(Jones et al. 1980). In a randomized crossover study 27
nondiabetic smokers and 16 nonsmokers received relatively
low single doses of 33.8 IU inhaled insulin AERx iDMS
(Himmelmann et al. 2003). Absorption of inhaled insulin was
significantly greater in smokers with a higher area under the
curve (AUC (0–6 h)), Cmax and tmax. 
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The effects of smoking cessation and resumption on the
absorption of Exubera have also been investigated. Two
randomized, crossover studies demonstrated that Exubera
absorption was two- to three-fold greater in smokers compared
with nonsmokers prior to cessation of smoking (Sha et al. 2002;
Becker et al. 2003). These studies also showed that the
absorption of Exubera decreases during nonsmoking periods and
subsequently increases once smoking is resumed (Sha et al.
2002; Becker et al. 2003). 
Asthma
Individuals with asthma have altered pulmonary function.
Therefore, the absorption of inhaled insulin may be affected and
the airways of asthmatics may develop a hypersensitivity
reaction. An open-label, parallel-group study examined the
effects of inhaled insulin (AERx iDMS) on pulmonary function in
17 asthmatic nondiabetic subjects compared with 28 healthy
individuals (Henry et al. 2003a). The pharmacokinetics and
pharmacodynamics of inhaled insulin were also determined.
Asthmatic subjects absorbed less insulin than healthy subjects
[insulin AUC(0–360 min) 1.45 × 106 pmol/min per kg healthy
volunteers vs 1.07 × 106 pmol/min per kg asthmatic patients
(P=0.013)]. These results suggest that diabetic patients with
asthma may need to inhale more insulin than patients with
normal respiratory function in order to achieve similar glycemic
control. 
Age
Convenience and ease of use of the Exubera inhaler should be
studied in elderly patients with diabetes because the device may
have limitations with regards to dexterity, and elderly patients’
ability to breathe deeply may be compromised.
It is also necessary to conduct pharmacokinetic studies with
Exubera in elderly patients with diabetes to determine the effect
of lung aging on the bioavailability of inhaled insulin (Belmin &
Valensi 2003). An open-label trial investigating the
pharmacokinetics and pharmacodynamics of inhaled insulin
(AERx iDMS) demonstrated that the intrasubject variability in
elderly patients (≥65 years) was similar to that for young patients
(18–45 years) with a comparable pharmacokinetic profile (Henry
et al. 2003b). However, glucose reduction was significantly less in
elderly patients and the authors suggested that elderly diabetic
patients may need to inhale more insulin to achieve similar
glycemic control.
Furthermore, a trial comparing the pharmacokinetics and
pharmacodynamics of Exubera with subcutaneous insulin in
elderly patients (mean age 72 years) demonstrated that Exubera
is absorbed more rapidly and has a similar or better intrasubject
variability than subcutaneous insulin (Henry et al. 2003c).
There are insufficient studies to be able to judge utility in elderly
patients. Further well-designed studies are required to investigate
the effects on insulin absorption and hence the dosage
requirements in these patient groups. 
Outcomes summary
Glycemic control with Exubera inhaled insulin before meals in
conjunction with an injected basal insulin is comparable to that in
patients receiving multiple daily injections, with no difference in
the incidence of hypoglycemia or weight gain. 
A major benefit of Exubera in comparison to subcutaneous insulin
appears to be the improvement in patient treatment satisfaction
which is presumed to be related to its ease of use, leading to
better adherence to treatment. However, there is limited evidence
to show the effects of long-term Exubera treatment on pulmonary
function. 
In summary, current evidence suggests that Exubera is an
alternative to short-acting subcutaneous insulin therapy providing
a further choice for the treatment of patients with type 1 or type 2
diabetes. However, the availability of inhaled insulin would not
mean an end to injections, as patients with type 1 diabetes, and
many patients with type 2 diabetes, would still require daily
injections of basal insulin. Exubera may lead to earlier introduction
of insulin therapy in type 2 diabetes based on improved patient
acceptance and improved glycemic control and may eliminate the
need for mealtime insulin injections in diabetic patients requiring
insulin therapy. There is also limited evidence available for the
efficacy and safety in patient groups with compromised lung
capacity (e.g. smokers, asthmatics). The improved acceptability
of Exubera translating into better diabetes control may have a
substantial impact on the burden of disease. Further studies are
essential to determine Exubera’s place in therapy compared with
other inhaled insulin delivery systems currently in development. 
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